Bioventus accelerates vesting of former Interim CEO Bihl's equity awards upon CEO transition

Bioventus Inc.

Board accelerated all outstanding and unvested equity awards of Anthony P. Bihl III effective January 9, 2024.
Equity awards were originally set to vest in April 2024; acceleration was discretionary under award terms.
Bihl served as Interim President and CEO since April 2023; Robert E. Claypoole succeeded him on January 10, 2024.
Acceleration based on Bihl's performance and contributions to the Company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Claypoole

President and Chief Executive Officer

BVS · Bioventus Inc.

Effective: 2024-01-10
Filed: January 12, 2024, 6:59 PM ET

As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.

Departed

Anthony P. Bihl III

Interim President and Chief Executive Officer

BVS · Bioventus Inc.

Effective: 2024-01-10
Successor: Robert E. Claypoole
Filed: January 12, 2024, 6:59 PM ET

As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..

Action: succeeded
Role: President and Chief Executive Officer

Exact text from the filing

As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..

Role: Interim President and Chief Executive Officer

Exact text from the filing

As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.

View on SEC.gov

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-007640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.